Business
Here’s how much weight loss drugs could cost you under Trump’s deals with Eli Lilly, Novo Nordisk
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty Images
President Donald Trump on Thursday struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs.
Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350 starting next year, depending on the dosage and insurance coverage a patient has, Trump administration officials said.
Existing GLP-1s, including Eli Lilly’s obesity injection Zepbound and Novo Nordisk’s competitor Wegovy, carry list prices above $1,000 a month, which has prevented many patients from taking them. Both companies have introduced lower cost options for people paying in cash and purchasing the drugs directly through their websites.
But the deals with Trump, as part of his “most favored nation” policy, take those efforts to expand access even further. Here’s how much weight loss drugs could cost for patients under the new agreements, based on the details shared so far.
Medicare
Medicare has covered GLP-1 drugs for diabetes and some other medical conditions: for example, Wegovy for slashing cardiovascular risks. But under the new deals, Medicare will start covering the drugs for obesity for the first time starting in mid-2026, which could allow more seniors to qualify for them and spur more private insurers to cover them.
Certain Medicare patients will pay a copay of $50 per month for all approved uses of GLP-1 drugs, including diabetes and obesity treatment.
But the Trump administration is putting some constraints on which Medicare beneficiaries will be eligible to receive GLP-1s for obesity and cardiovascular and metabolic benefits.
Patients are eligible if they fall into these three cohorts:
- The first includes those who are overweight — with a body mass index greater than 27 — or with prediabetes or established cardiovascular disease.
- The second group is people with obesity – with a BMI greater than 30 – and uncontrolled hypertension, kidney disease or heart failure.
- The third group is patients with severe obesity, or anyone with a BMI greater than 35.
Eli Lilly and Novo Nordisk voluntarily agreed to reduce the prices the government pays for existing GLP-1 drugs already approved for diabetes and other uses to $245 a month, across all non-starting doses. Savings generated by those price reductions will allow Medicare to start paying that same price point for GLP-1s for patients with obesity and a high metabolic or cardiovascular risk.
Direct-to-consumer
The agreement will also allow patients to get GLP-1s on direct-to-consumer platforms at steeper discounts than they already receive through drugmakers’ existing sites.
On TrumpRx – the government’s direct-to-consumer platform for buying prescription drugs with cash expected to launch next year – the average monthly cost for Wegovy, Zepbound and other injectable GLP-1s will start at $350 and drop to $250 within the next two years, according to senior administration officials.
Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $149 per month on TrumpRx, Medicare and Medicaid. Under the deals announced Thursday, Eli Lilly will get fast-track reviews of its forthcoming pill.
Eli Lilly on Thursday said it would lower prices by $50 on its own direct-to-consumer platform, LillyDirect, which already offers Zepbound and other drugs at a discount to cash-paying patients. The multidose pen of Zepbound will be available for $299 per month at the lowest dose, with additional doses being priced up to $449 per month.
Eli Lilly’s pill, once approved, will be available at the lowest dose starting at $149 per month
Medicaid
State Medicaid coverage of GLP-1 drugs for obesity is spotty.
But Novo Nordisk and Eli Lilly agreed to extend lower government pricing for their GLP-1 drugs – $245 per month across all other non-starting doses – to all 50 Medicaid programs for all covered uses.
States will have to opt into those prices, meaning some may not. Check with your state government about coverage.
Business
Logistics IPO: Yatayat Corporation files Sebi papers to raise funds; growth surge puts road freight firm in focus – The Times of India
Logistics and transportation services provider Yatayat Corporation India Ltd has filed draft papers with markets regulator Sebi to raise funds through an initial public offering, as the road freight segment continues to see strong demand, PTI reported.According to the draft red herring prospectus (DRHP), the proposed IPO will comprise a fresh issue of up to 77 lakh equity shares along with an offer for sale (OFS) of up to 56 lakh equity shares by a promoter, taking the total offer size to as many as 1.33 crore shares.The company said proceeds from the fresh issue will be used primarily to meet working capital requirements and for general corporate purposes.Yatayat Corporation operates in the road logistics space, with a focus on Full Truck Load (FTL) transportation, offering point-to-point freight movement across major logistics corridors in the country. Its operations are supported by a network of 34 branches and one warehouse spread across 12 states.The company services a diversified client base spanning agriculture and agri-inputs, building materials and construction, chemicals and allied industries, energy and power, engineering and industrial manufacturing, IT and technology solutions, metals and mining, textiles and apparel, as well as other industrial and consumer segments.On the financial front, Yatayat Corporation reported revenue from operations of Rs 448.13 crore in FY25, up from Rs 348.34 crore in FY24. Profit after tax rose to Rs 30 crore in FY25, compared with Rs 15 crore in the previous financial year.Unistone Capital has been appointed as the sole book-running lead manager to the issue, the draft papers showed.
Business
WH Smith to claw back £1.5m from ex-bosses after accounting scandal
WH Smith is to claw back around £1.5 million in overpaid bonuses from former bosses following an accounting blunder at the retail firm’s US arm.
The travel retail specialist confirmed last week it is being investigated by the UK’s financial watchdog after it overstated profits for its North American business by as much as £50 million due to issues with its audit process.
Carl Cowling resigned as WH Smith’s chief executive last month after a report by Deloitte confirmed the accounting problems.
The company said on Wednesday in its annual report that annual bonus payments for Mr Cowling and former finance chief Robert Moorhead have been recalculated for 2023 and 2024.
It has also recalculated the payment of long-term share bonuses from a 2021 scheme for executives.
WH Smith said it overpaid Mr Cowling £516,000 in cash and 60,182 deferred shares worth £374,933 based on the latest closing price for the firm.
It overpaid Mr Moorhead by £372,000 in cash and £272,493 worth of shares.
It said it would now seek to “claw back” both of these payments from the former bosses.
WH Smith also confirmed that it did not pay annual or long-term bonuses to Mr Cowling for the past financial year.
As a result, his total pay deal tumbled to £724,000 for the year to August 2025, from £2.71 million for the same period a year earlier.
The retailer told investors last week that it had kickstarted a remediation plan, which aims to strengthen its governance and controls, ensure processes are aligned across the group, and enact cultural change involving training and monitoring.
Its board is currently searching for a permanent group chief executive.
WH Smith is now focused solely on its 1,300 shops in global travel locations, including at airports and train stations, after selling its high street chain of about 480 shops to Hobbycraft owner Modella Capital in June.
As part of the deal, the WH Smith name is disappearing from British high streets and being replaced by brand TGJones.
The slimmed-down business reported a pre-tax profit of £108 million for the year to the end of August, excluding what it deems one-off costs.
Business
RBI Postpones Phase 2 Cheque Clearing, Modifies Presentation And Confirmation Hours
RBI Guidelines For Cheque Clearing Time: The Reserve Bank of India (RBI) said on Wednesday that it has delayed the rollout of Phase 2 of the faster cheque clearance system by banks. The new phase was earlier set to begin on January 3, 2026. The RBI also announced changes to cheque processing timings. Cheques can now be presented between 9 am and 3 pm, while banks will have time from 9 am to 7 pm to confirm or reject them.
“Implementation of phase 2 is being postponed until further notice, to allow more time to banks to streamline their processes,” according to the RBI statement. Phase 1 of the system, which was implemented earlier this year, will continue to operate as usual.
RBI Phase 2 Guidelines
Under the proposed Phase 2 guidelines, banks are required to clear or reject any cheque deposited over the counter within just three hours. This is expected to be a major relief for customers, making payments faster and more efficient once the process starts.
RBI Rolls Out Cheque Truncation System
The RBI introduced continuous clearance under the Cheque Truncation System (CTS) to speed up and simplify cheque clearing. Instead of the old batch system, cheques are now processed using digital images and electronic data. This means banks no longer need to physically transfer cheques, making the process faster and more efficient.
RBI Phase 1 Single Presentation Window
From October 4, 2025, Phase 1 brought in a single, continuous cheque presentation window during the day. Instead of waiting for fixed clearing batches, banks now scan cheques as they receive them and send the cheque images along with MICR data to the clearing house.
Once the drawee bank gets the cheque image, it checks the details and sends an approval or rejection electronically. If the bank does not respond by the end of the confirmation window, the cheque is automatically treated as approved and settled.
RBI Phase 2 Plan For Cheque Clearance
Phase 2, which was planned to start from January 3, 2026, was meant to further expedite the clearance of cheques to ensure greater convenience for bank customers. Banks would get just three hours to approve or reject a cheque after receiving its image.
If a bank failed to respond within this time, the cheque would be automatically approved and settled. This would have pushed banks to process cheques more quickly and helped customers get their money sooner. However, since phase 2 has been deferred, cheque clearing will continue under the present Phase 1 system, which does not have to follow the three-hour deadline. (With IANS Inputs)
-
Fashion7 days agoIndonesia’s thrift surge fuels waste and textile industry woes
-
Tech7 days agoT-Mobile Business Internet and Phone Deals
-
Business7 days agoBP names new boss as current CEO leaves after less than two years
-
Sports7 days agoPKF summons meeting after Pakistani player represents India in kabaddi tournament
-
Entertainment7 days agoIndia streamlines visa rules in boost for Chinese professionals
-
Sports7 days agoUWCL grades for all 18 teams: Leuven get A+; Barça an A-, PSG fail
-
Business1 week agoFord to record $19.5 billion in special charges related to EV pullback
-
Entertainment7 days agoRadiation fears rise after cracks found in $2 billion Chernobyl shield
